Starpharma Holdings Ltd has released a press release.
Interim Report and Half-Yearly Financial Results
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Response to ASX Aware Letter
- VivaGel condom receives final regulatory approval in Japan
- US FDA requests further data for VivaGel BV approval
- US VivaGel BV licensed for A$142M milestones plus royalties
- DEP products outperform in human pancreatic cancer model
Later from Starpharma
- Starpharma receives $4.0M R&D tax incentive refund
- First VivaGel BV launch globally in Australia by Aspen
- DEP irinotecan combination outperforms in colon cancel model
- Starpharma signs second oncology agreement with AstraZeneca
- VivaGel BV launched in Europe
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma